C-MER Eye Care Holdings Limited announced that based on the unaudited financial information currently available for the year ended 31 December 2023, the Company is expected to realise a turnaround and achieve a profit attributable to the equity holders of the Company in the range of HKD 60.0 million to HKD 65.0 million, as compared with a loss attributable to equity holders of HKD 21.9 million for the year ended 31 December 2022. The expected increase in profit attributable to equity holders of the Company was primarily driven by an over 30% increase in revenue generated from medical service to approximately HKD 1,900.0 million in FY2023 from HKD 1,433.6 million in FY2022, partially net off by the reduction in revenue generated from sale of COVID-19 related medical consumables to approximately HKD 19.0 million in FY2023 from HKD 298.3 million in FY2022.